Molecular Partners (NASDAQ:MOLN – Get Free Report) released its earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08, Zacks reports.
Molecular Partners Stock Up 2.9%
NASDAQ MOLN traded up $0.10 during trading hours on Friday, hitting $3.63. 1,523 shares of the company were exchanged, compared to its average volume of 4,315. The stock has a market cap of $146.74 million, a PE ratio of -2.13 and a beta of 1.11. The stock has a 50-day moving average price of $4.05 and a 200 day moving average price of $4.18. Molecular Partners has a 52 week low of $3.51 and a 52 week high of $5.36.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on MOLN shares. HC Wainwright reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.38.
Get Our Latest Report on Molecular Partners
About Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.
Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.
Featured Articles
- Five stocks we like better than Molecular Partners
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
